Background: Residual shunt is observed in up to 25% of patients after patent foramen ovale
(PFO) closure, but its long-term influence on stroke recurrence currently is unknown …

Background Percutaneous closure of patent foramen ovale (PFO) has been shown to be
superior to medical treatment alone for prevention of recurrent stroke after cryptogenic …

Aims The preferred antithrombotic strategy for secondary prevention in patients with
cryptogenic stroke (CS) and patent foramen ovale (PFO) is unknown. We pooled multiple …

This article has been corrected. The original version (PDF) is appended to this article as a
Supplement. Background: The optimal strategy for preventing recurrent stroke in patients …

Up to a third of strokes are rendered cryptogenic or of undetermined etiology. This number is
specifically higher in younger patients. At times, inadequate diagnostic workups, multiple …

Background In patients with cryptogenic stroke, transcatheter (TC) closure of a patent
foramen ovale (PFO) has not been shown to better prevent recurrent vascular events than …

In about a quarter of ischaemic strokes the cause is undetermined, because the
investigation is incomplete or delayed, because there are multiple causes or because the …

Patent foramen ovale (PFO) is a common benign finding in healthy subjects, but its
prevalence is higher in patients with stroke of unclear cause (cryptogenic stroke). PFO is …

Stroke is a devastating condition with significant morbidity and mortality worldwide.
Antithrombotic therapy plays a crucial role in both primary and secondary prevention of …

Background We aimed to assess trends in hospitalization, outcomes, and resource
utilization among patients admitted with adult congenital heart disease (ACHD). Methods …